Actively Recruiting
Phase 3 Study to Test the Safety and Effectiveness of STSA-1002 Injection in Adults With Acute Respiratory Distress Syndrome
Led by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Updated on 2026-01-02
406
Participants Needed
15
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of STSA-1002 injection in adults with acute respiratory distress syndrome ARDS. This Phase 3 randomized, double-blind, placebo-controlled trial aims to assess whether STSA-1002 can improve outcomes in patients suffering from this serious lung condition caused by respiratory viral infection. Participants must meet specific diagnostic criteria for ARDS and be within certain timeframes from symptom onset or worsening. The study compares two groups one receiving basal treatment plus STSA-1002 intravenous infusion and the other receiving basal treatment plus a placebo injection. Both treatment groups receive standard care alongside the investigational drug or placebo. The trial includes a 28-day period after the first dose, during which primary and secondary outcomes are measured, including mortality rates, respiratory support needs, and length of hospital stay. Participants will be closely monitored with evaluations including respiratory support assessments, organ function scores, and length of ICU and hospital stays. Researchers will track 28-day and 60-day mortality rates, changes in respiratory function, and ventilator-free days. The study involves baseline and follow-up tests and observations over the course of the treatment period to gather comprehensive safety and effectiveness data.
CONDITIONS
Brief Title
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
Research Team
A
Aiping Sun
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here